Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Leuk Res. 2013 Dec 11;38(3):329–333. doi: 10.1016/j.leukres.2013.12.001

Table 3.

Patient outcomes in the four phase II tipifarnib studies of S0432

600 mg bid day 1–21 (n=80) 600 mg bid d 1–7, 15–21 (n=85) 300 mg bid day 1–21 (n=82) 300 mg bid d 1–7, 15–21 (n=84)
CR, CRi, PR 16% 12% 20% 5%
95% CI 9–26% 6–20% 12–30% 1–12%
CR 8% 5% 11% 1%
CRi 8% 6% 4% 4%
PR 1% 1% 5% 0%
Fatal toxicity 8% 4% 2% 0%
Median survival 104 days 116 days 111 days 106 days
12 month overall survival 13% 25% 28% 15%
12 month relapse-free survival 11% 20% 17% 0%